The results from the phase 2 trial of this nasal spray sound extremely promising and the company are in discussions to ramp up manufacturing -
“ Our trial included patients with a variant of concern and high viral loads yet still demonstrated significant reductions in the levels of SARS-CoV-2”
‘Patients treated with SaNOtize’s spray saw an average viral log reduction of 1.362 in the first 24 hours,
which corresponds to a decline of around 95%. Within 72 hours the viral load plummeted by more than 99%. No adverse events were recorded in the UK trial nor in earlier Canadian trials that saw over 7,000 patients testing the self-administered treatment.’
Based on the trial results,
SaNOtize is planning to submit emergency use applications to regulatory authorities in the UK and Canada for the treatment and prevention of Covid-19.
SaNOtize's nitric oxide nasal spray has been found to dramatically reduce Covid-19 viral load in infected patients, UK Phase II trial finds.
www.clinicaltrialsarena.com